Cue Biopharma Files Proxy Materials
Ticker: CUE · Form: DEFA14A · Filed: May 27, 2025 · CIK: 1645460
Sentiment: neutral
Topics: proxy-filing, sec-filing, company-update
TL;DR
Cue Biopharma filed proxy docs, no fee. Shareholders get the scoop.
AI Summary
Cue Biopharma, Inc. filed a Definitive Additional Materials proxy statement on May 27, 2025. This filing is related to the company's proxy materials and does not involve a fee, as indicated by the 'No fee required' checkbox. The company, formerly known as Imagen Biopharma, Inc., is based in Boston, MA.
Why It Matters
This filing provides important information to shareholders regarding company matters, as required by the SEC for public companies.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain information about significant financial events or strategic shifts.
Key Players & Entities
- Cue Biopharma, Inc. (company) — Registrant
- Imagen Biopharma, Inc. (company) — Former company name
- 40 Guest Street, Boston, Massachusetts 02135 (location) — Business and mailing address
- May 27, 2025 (date) — Filing date
FAQ
What type of filing is this?
This is a Definitive Additional Materials filing (DEFA14A) for Cue Biopharma, Inc.
When was this filing made?
The filing was made on May 27, 2025.
Is there a filing fee associated with this document?
No, the filing indicates 'No fee required'.
What is the company's business address?
The company's business address is 40 Guest Street, Boston, Massachusetts 02135.
Did Cue Biopharma have a previous name?
Yes, Cue Biopharma, Inc. was formerly known as Imagen Biopharma, Inc., with a name change date of June 17, 2015.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 27, 2025 regarding Cue Biopharma, Inc. (CUE).